10-Q: Cingulate Inc. Reports Q3 2024 Results, Progresses Towards NDA Submission for CTx-1301

Sentiment:

Quarterly Report 7 November 2024 7:56 AM

Cingulate Inc. announced its third quarter 2024 financial results, highlighting progress in clinical development and strategic financial activities.

Capital raiseThe company raised approximately $13.5 million through equity offerings during the quarter.The company increased the maximum aggregate offering price of the shares of the Company's common stock issuable under the ATM Agreement from $15.2 million to $19.7 million.The company is evaluating various strategies to obtain additional funding, which may include additional offerings of equity, issuance of debt, or other capital sources, including potential collaborations with other companies or other strategic transactions.

Worse than expectedThe company reported a net loss of $3.2 million for the quarter, which is worse than the previous quarter and indicates ongoing financial challenges.The company has an accumulated deficit of $102.4 million, which is worse than the previous quarter and indicates ongoing financial challenges.The company has stated there is substantial doubt about the company's ability to continue as a going concern within one year after the date that the financial statements are issued.

Summary

Cingulate Inc. reported a net loss of $3.2 million for the third quarter of 2024, compared to a $6.0 million loss in the same period of 2023.
The company's research and development expenses decreased significantly to $1.4 million in Q3 2024 from $3.9 million in Q3 2023, primarily due to reduced clinical trial activity.
General and administrative expenses remained relatively stable at $1.9 million in Q3 2024 compared to $1.8 million in Q3 2023.
Cingulate's cash and cash equivalents stood at $10 million as of September 30, 2024.
The company is targeting a New Drug Application (NDA) submission for CTx-1301 in mid-2025.
Cingulate completed a one-for-twelve reverse stock split on August 9, 2024.
The company raised approximately $13.5 million through equity offerings during the quarter.
The company has an accumulated deficit of approximately $102.4 million as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical development and some financial activity, the company's ongoing losses, dependence on capital raises, and going concern warning temper the positive aspects. The sentiment is cautiously negative.

Positives

The company has made significant progress towards its NDA submission for CTx-1301.
Cingulate has successfully raised capital through various equity offerings.
The company has reduced its operating expenses, particularly in research and development.
The company has secured a European patent for CTx-1301.
The company has made progress in the development of CTx-2103, achieving a triple release of buspirone in a formulation study.

Negatives

Cingulate continues to incur significant operating losses.
The company has an accumulated deficit of $102.4 million.
The company is dependent on raising additional capital to fund its operations.
There is substantial doubt about the company's ability to continue as a going concern within one year after the date that the financial statements are issued.

Risks

The company's ability to generate revenue is dependent on the successful development and commercialization of its product candidates.
Cingulate may not be able to obtain regulatory approvals for its product candidates.
The company may not be able to raise additional capital on acceptable terms, or at all.
The company's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of its securities.
The company is subject to risks associated with any pre-clinical stage pharmaceutical company that has substantial expenditures for research and development.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the near term as it continues clinical development for its product candidates, primarily CTx-1301, and seeks marketing approval and eventual commercialization of its product candidates. The company is targeting an NDA submission for CTx-1301 in mid-2025.

Management Comments

Management is evaluating various strategies to obtain additional funding, which may include additional offerings of equity, issuance of debt, or other capital sources, including potential collaborations with other companies or other strategic transactions.
Management believes that they can seek and win approval of CTx-2103 under the 505(b)(2) pathway, which typically requires less time and resources than the 505(b)(1) full NDA pathway.

Industry Context

Cingulate is operating in the competitive biopharmaceutical industry, focusing on developing treatments for ADHD and anxiety. The company's strategy of using its proprietary drug delivery platform to create once-daily, multi-dose tablets aligns with the industry's trend towards improving patient convenience and adherence. The company's focus on the 505(b)(2) regulatory pathway is a common strategy for companies seeking to reduce development time and costs.

Comparison to Industry Standards

Cingulate's R&D spending is typical for a pre-revenue biopharmaceutical company, with a significant portion allocated to clinical trials and manufacturing.
The company's reliance on equity financing is common for early-stage biotech companies, but the need for frequent capital raises can be dilutive to existing shareholders.
The company's focus on the 505(b)(2) regulatory pathway is a common strategy for companies seeking to reduce development time and costs, similar to companies like Supernus Pharmaceuticals and Tris Pharma.
The company's development of a once-daily, multi-dose tablet for ADHD is similar to the approach taken by companies like Ironshore Pharmaceuticals, which developed Concerta, an extended-release methylphenidate product.
The company's development of CTx-2103 for anxiety is in line with the industry's focus on addressing mental health conditions, with companies like Axsome Therapeutics also developing novel treatments for anxiety.

Related Party Transactions

In August 2022, the Company received $5.0 million of debt financing from Werth Family Investment Associates LLC (WFIA).
In May 2023, the Company received an additional $3.0 million of debt financing from WFIA.
On September 8, 2023, the Company and CTx entered into a note conversion agreement with WFIA.
On January 25, 2024, the Company and CTx entered into another note conversion agreement with WFIA.

Stakeholder Impact

Shareholders face the risk of dilution from future equity offerings.
Employees may be affected by cost containment measures and potential future restructuring.
Customers (patients) may benefit from the development of new treatment options for ADHD and anxiety.
Suppliers and creditors may be impacted by the company's financial situation and ability to meet its obligations.

Next Steps

The company will continue to work towards the NDA submission for CTx-1301, targeted for mid-2025.
The company will continue to evaluate strategic partnerships for CTx-1301.
The company will continue to develop CTx-1302 and CTx-2103, pending additional capital resources.
The company will continue to seek additional funding through various means.

Key Dates

Date	Description
2022-08-09	Date of the original promissory note with Werth Family Investment Associates LLC (WFIA).
2023-01-01	Start date of the At-the-Market Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC (HCW).
2023-04-24	Date of the purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park).
2023-05-01	Date of the amended and restated note with WFIA.
2023-08-09	Date of the one-for-twelve reverse stock split.
2023-09-08	Date of the note conversion agreement with WFIA.
2023-11-30	Date of the one-for-twenty reverse stock split.
2024-01-25	Date of the second note conversion agreement with WFIA.
2024-02-02	Date of the public offering (the February 2024 Offering).
2024-02-05	Initial exercise date of the Series A and Series B warrants.
2024-03-17	Date the exercise price of the Series A and Series B Warrants was lowered.
2024-06-28	Date of the inducement offer letter agreement (June 2024 Warrant Inducement).
2024-07-01	Closing date of the June 2024 Warrant Inducement.
2024-08-09	Date of the one-for-twelve reverse stock split.
2024-08-14	Date a European patent for CTx-1301 was issued.
2024-09-30	End of the quarterly period.
2024-10-15	Date the maximum aggregate offering price of the shares of the Company's common stock issuable under the ATM Agreement was increased.
2024-11-06	Date as of which 3,212,233 shares of the registrants common stock were issued and outstanding.
2024-11-07	Date the interim financial statements were issued.

Keywords

Cingulate, biopharmaceutical, ADHD, CTx-1301, CTx-1302, CTx-2103, NDA, clinical trials, reverse stock split, equity offering, pharmaceutical, drug delivery, PTR technology, anxiety, buspirone

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.